Heron Therapeutics (HRTX) Stock
Small cap biopharma for oncology supportive care and pain. Here's the price, business snapshot, and what's worth knowing about Heron Therapeutics in May 2026.
Heron Therapeutics, Inc. (HRTX) is a small‑cap biopharmaceutical company focused on developing and commercialising treatments for supportive care in oncology and acute pain management. The company has pursued a mix of marketed products and partnered programmes aimed at reducing chemotherapy‑related side effects and improving postsurgical pain control. With a market capitalisation of approximately $238.3 million, Heron operates in a high‑volatility, data‑driven sector where clinical results, regulatory actions and commercial uptake can materially affect valuation. Revenue streams for firms of this size are often lumpy and may rely on licensing deals or collaborations; additional capital raises are not uncommon. This summary is educational and not personalised investment advice — potential investors should review the latest financial statements, regulatory filings and investor presentations, and consider their risk tolerance and diversification needs before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Heron Therapeutics' stock, expecting its price to rise significantly.
Financial Health
Heron Therapeutics is generating good revenue and cash flow, indicating a positive financial outlook.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring HRTX
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalyst Watch
Upcoming clinical readouts and regulatory milestones can move the share price; positive data may lift sentiment, though trial outcomes are uncertain.
Commercial & Partnerships
Revenue often depends on product uptake and licensing deals; partnerships can broaden reach but terms and milestone risks vary.
Small‑cap Volatility
With a market cap near $238M, liquidity can be limited and price swings larger than for bigger peers; consider diversification and risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
